A Phase I Study of LY3502970 in Healthy Participants

Lilly

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: LY3502970; Drug: [14C]-LY3502970

Study type: Interventional

Funder types: Industry

Identifiers

NCT06085482

J2A-MC-GZGO (Other Identifier)

18596

Details and patient eligibility

About

The main purpose of this study is to evaluate how much of the study drug (LY3502970) and the radioactive substance 14C incorporated LY3502970 gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 9 weeks for each participant.

Enrollment: 10 patients

Sex: All

Ages: 21 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Are overtly healthy as determined by medical evaluation
• Participants with body weight of 45 kilograms (kg) or more and body mass index within the range 18.5 to 35.0 kilograms per meter squared (kg/m²), inclusive
• Males who agree to use highly effective or effective methods of contraception and women not of childbearing potential may participate in this study

Exclusion criteria

• Participants who have known allergies to LY3502970, related compounds, or any components of the formulation
• Women who are lactating and women of child bearing potential (WOCBP) are excluded from the study
• Participants who regularly use known drugs of abuse or show positive findings on drug screen

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

LY3502970 + [14C]-LY3502970

Experimental group

Description:

Participants received a single oral dose of 1 milligram (mg) LY3502970 followed six hours later by an intravenous (IV) dose of approximately 21 microgram (μg) of LY3502970 radiolabeled with carbon-14 (\[14C\]-LY3502970) containing approximately 800 nanocurie (nCi) radioactivity.

Treatment:

Drug: [14C]-LY3502970

Drug: LY3502970